Molecular HIV surveillance

Did you know that molecular HIV surveillance (MHS) is the collection of HIV genetic data used to support local and state health departments in monitoring trends in HIV transmission and drug resistance? Learn more MHS and how health departments and CDC use this data to guide HIV prevention efforts.

 
 
White blood cells

What is MHS?

Curious about molecular HIV surveillance? Download 10 Molecular HIV Surveillance FAQs, a plain-language document that explains what MHS is and how it is used by health departments to identify transmission patterns and detect HIV drug resistance.

 
Colin Flynn.jpg
 
NYC's strategy to end the HIV epidemic

What can we learn from MHS data?

Colin Flynn, ScM, the Chief of the Center for HIV Surveillance, Epidemiology and Evaluation at the Maryland Department of Health explains what we can learn from MHS data.

 

How do health departments use MHS data to guide prevention efforts?

Learn NYC's strategy to end the HIV epidemic and how it is using MHS data to respond to HIV clusters and guide prevention efforts. Download the NYC Strategy to Ending the HIV Epidemic and Using Molecular HIV Surveillance Data to Guide Public Health Practice in NYC presentations.

 
Molecular HIV Surveillance Cluster Response and Community Engagement

How do health departments communicate MHS data to their communities?

As MHS evolves, the Houston Health Department is committed to moving forward in a thoughtful and meaningful way with strategic partners and community members. To learn how they use MHS data to response to HIV clusters and foster community engagement, download the health department's presentation slideshealth advisory from the Texas Department of State Health Services, community invitation from the mayor of Houston, MHS genotype cluster talking points referenced in Houston's Molecular HIV Surveillance Cluster Response and Community Engagement presentation.

 
Using surveillance data to identify molecular clusters

how does CDC use MHS data?

During this webinar, speakers from UCHAPS and the CDC will discuss the public health model for MHS, debunk myths about MHS, and identify benefits of MHS. Presentations will be followed by Q&A. 

Featured Speaker
Alexa Oster, MD, the Molecular HIV Surveillance Lead in the Division of HIV/AIDS Prevention at the Centers for Disease Control and Prevention

Click to download the presentation slidescluster guidance and intro to HIV evolution referenced in this webinar.


This resource was supported by the Cooperative Agreement, #NU65PS004588 funded by the Centers of Disease Control and Prevention. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the Centers of Disease Control and Prevention or the Department of Health and Human Services.